Biogen fills in some of the blanks on its trial of a high-dose version of Spinraza

A trial of Biogen’s spinal muscular atrophy (SMA) therapy Spinraza (nusinersen) suggests that a higher dose provides benefits to a broad range of patients—including those who have and have not been treated, as well as patients with early- and late-onset variations of the disorder.